In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor
- PMID: 1748061
- DOI: 10.1016/0168-8227(91)90050-n
In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor
Abstract
The effects of a high-glucose medium, insulin, and an aldose reductase inhibitor (ONO-2235) on sorbitol accumulation were compared in the human erythrocyte and the rabbit retina, while the effects of epinephrine on in vitro sorbitol accumulation were investigated in the human and rabbit retina. In both erythrocytes and the retina, linear increments of sorbitol accumulation were observed in a dose-dependent manner with 5 to 50 mM glucose. These increments were markedly inhibited by 100 microM ONO-2235 but not by insulin (400 microU/ml). In the presence of 5 mM glucose, a dose-dependent increase of the sorbitol content of the rabbit retina was seen following epinephrine stimulation (0.4-4.0 microM and this was markedly reduced by 100 microM ONO-2235. Moreover, both 50 mM glucose and 4.0 microM epinephrine increased the sorbitol content of the retina from a diabetic patient, and the glucose-induced increment in sorbitol was significantly reduced by 100 microM ONO-2235. Our data suggested that aldose reductase inhibitors might be useful for the treatment of diabetic retinopathy, since the polyol pathway appears to be an important factor in its pathogenesis, and that catecholamines might have some role in the activation of the retinal polyol pathway.
Similar articles
-
Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance tests.Horm Metab Res. 1991 May;23(5):226-9. doi: 10.1055/s-2007-1003658. Horm Metab Res. 1991. PMID: 1908433
-
Polyol pathway in tissues of spontaneously diabetic Chinese hamsters (Cricetulus griseus) and the effect of an aldose reductase inhibitor, ONO-2235.Comp Biochem Physiol B. 1991;98(4):637-40. doi: 10.1016/0305-0491(91)90268-i. Comp Biochem Physiol B. 1991. PMID: 1907900
-
Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma.Eur J Pharmacol. 1992 May 14;215(2-3):289-91. doi: 10.1016/0014-2999(92)90041-2. Eur J Pharmacol. 1992. PMID: 1396993
-
Aldose reductase / polyol inhibitors for diabetic retinopathy.Curr Pharm Biotechnol. 2011 Mar 1;12(3):373-85. doi: 10.2174/138920111794480642. Curr Pharm Biotechnol. 2011. PMID: 20939801 Review.
-
The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient.Exp Diabetes Res. 2007;2007:61038. doi: 10.1155/2007/61038. Exp Diabetes Res. 2007. PMID: 18224243 Free PMC article. Review.
Cited by
-
Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.Br J Ophthalmol. 2002 Aug;86(8):860-3. doi: 10.1136/bjo.86.8.860. Br J Ophthalmol. 2002. PMID: 12140204 Free PMC article. Clinical Trial.
-
Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.Drugs Aging. 1993 Nov-Dec;3(6):532-55. doi: 10.2165/00002512-199303060-00007. Drugs Aging. 1993. PMID: 8312678 Review.
-
Thermal stress and diabetic complications.Int J Biometeorol. 1995 Jan;38(2):57-9. doi: 10.1007/BF01270659. Int J Biometeorol. 1995. PMID: 7698855
-
Up-regulation of aldolase A and methylglyoxal production in adipocytes.Br J Pharmacol. 2013 Apr;168(7):1639-46. doi: 10.1111/bph.12046. Br J Pharmacol. 2013. PMID: 23126339 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources